• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

1362850-20-1 (Seletalisib)

1

Identification

Seletalisib Seletalisib
Name Seletalisib
Formula C23H14ClF3N6O
MW 482.85
CAS No. 1362850-20-1
EINECS
Smiles FC(F)(F)[[email protected]@H](C1=CC(C=CC=C2Cl)=C2N=C1C3=CN(=O)=CC=C3)NC4=NC=NC5=C4N=CC=C5
Synonyms (R)-3-(8-chloro-3-(2,2,2-trifluoro-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl)quinolin-2-yl)pyridine 1-oxide
InChI InChI=1S/C23H14ClF3N6O/c24-16-6-1-4-13-10-15(18(31-19(13)16)14-5-3-9-33(34)11-14)21(23(25,26)27)32-22-20-17(29-12-30-22)7-2-8-28-20/h1-12,21H,(H,29,30,32)/t21-/m1/s1
2

Introduction

immunomodulator, phosphatidylinositol 3-kinase inhibitor

Background Information

Seletalisib is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by UCB.It is a Immunomodulator. Phaes I clinical trials for Plaque psoriasis, phaes II clinical trials for Sjogren's syndrome and phaes III clinical trials for Immunodefic ......by BOC Sciences
Seletalisib (UCB5857) is potent and selective PI3Kδ inhibitor with an IC50 of 12 nM. ......by MedChemexpress Co., Ltd.
Seletalisib, also known as UCB-5857, is a potent and selective PI3 kinase inhibitor, which may be useful for the treatment of immune-inflammatory diseases. ......by MedKoo Biosciences, Inc.
Seletalisib (UCB-5857) is a potent, ATP-competitive, and selective PI3Kδ inhibitor with IC50 of 12 nM; shows significant selectivity to PI3Kδ with respect to the other class I PI3K isoforms (204-303 fold); blocks AKT phosphorylation following activation of the B-cell receptor in a B-cell line; blocks human T-cell production of several cytokines from activated T-cells, and inhibits B-cell proliferation and cytokine release; dose-dependently inhibits anti-CD3-antibody-induced interleukin 2 release in mice.PsoriasisPhase 3 Clinical ......by ProbeChem
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000071592

Storage condition

Solubility

DMSO: ≥83.3 mg/mL by CHEMSCENE, LLC
DMSO: ≥83.3 mg/mL by MedChemexpress Co., Ltd.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
Seletalisib UCB Pharma|Parexel Psoriasis 2013/8/1 Phase 1
Seletalisib UCB Celltech|Parexel|UCB Pharma Healthy Volunteers 2014/8/1 Phase 1
Seletalisib UCB Celltech|PRA Health Sciences|UCB Pharma Primary Sjogren's Syndrome 2015/10/1 Phase 2
7

Safety Data of Seletalisib

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
BOC Sciences
CHEMSCENE, LLC 1mg/USD132();5mg/USD396() USA
MedChemexpress Co., Ltd. 1mg/USD132();5mg/USD396() USA
MedKoo Biosciences, Inc. USA
ProbeChem
Shanghai Haoyuan Chemexpress Co., Ltd. 1mg/USD132();5mg/USD396() China
10

Related Products

Other Forms of 1362850-20-1

Name CAS No Formula MW

Recommended Compounds in PI3K

Name CAS No Formula MW
MLN1117 1268454-23-4 C19H17N5O3 363.37
TGR-1202 1532533-67-7 C31H24F3N5O3 571.55
PI-3065 955977-50-1 C27H31FN6OS 506.64
Isorhamnetin 480-19-3 C16H12O7 316.26
BSF-466895 262442-90-0 C29H32Cl2FN7O2S 632.58
SAR245409 934493-76-2 C13H14N6O 270.29
HS-173 1276110-06-5 C21H18N4O4S 422.46
GDC-0032 1282512-48-4 C24H28N8O2 460.53
PF-4989216 1276553-09-3 C18H13FN6OS 380.4
CAL-130 (Hydrochloride) 1431697-78-7 C23H23ClN8O 462.93
CNX-1351 1276105-89-5 C30H35N7O3S 573.71
Quercetin 117-39-5
AS-252424 900515-16-4 C14H8FNO4S 305.28
CAY10505 1218777-13-9 C14H8FNO3S 289.28
CUDC-907 1339928-25-4 C23H24N8O4S 508.55
CAL-130 1431697-74-3 C23H22N8O 426.47
VS-5584 1246560-33-7 C17H22N8O 354.41
CH5132799 1007207-67-1 C15H19N7O3S 377.42
Duvelisib 1201438-56-3 C22H17ClN6O 416.863
XL-147 934526-89-3 C25H25ClN6O4S 541.02

Recommended Compounds in Same Indication

Name CAS No Formula MW
AN-2728 906673-24-3 C14H10BNO3 251.05
BMS-582949 623152-17-0 C22H26N6O2 406.48
SCH 527123 473727-83-2 C21H23N3O5 397.42
Sotrastaurin 425637-18-9 C25H22N6O2 438.48
Avatrombopag 570406-98-3 C29H34Cl2N6O3S2 649.65
Apremilast 608141-41-9 C22H24N2O7S 460.5
Talarozole 201410-53-9 C21H23N5S 377.51
Dimethyl fumarate 624-49-7 C6H8O4 144.13
VX-765 273404-37-8 C24H33ClN4O6 509.0
Calcitriol 32222-06-3 C27H44O3 416.64
Tofacitinib (citrate) 540737-29-9 C22H28N6O8 504.49
Brivaracetam 357336-20-0 C11H20N2O2 212.2887
Calcipotriol 112965-21-6 C27H40O3 412.6
(3R,4S)-Tofacitinib 1092578-46-5 C16H20N6O 312.37
(3S,4S)-Tofacitinib 1092578-47-6 C16H20N6O 312.37
(3S,4R)-Tofacitinib 1092578-48-7 C16H20N6O 312.37
BMS-582949 (hydrochloride) 912806-16-7 C22H27ClN6O2 442.94
Heparin 9005-49-6 C26H42N2O37S5 1134.93
Vadadustat 1000025-07-9 C14H11ClN2O4 0.0
Tenapanor 1234423-95-0 C50H66Cl4N8O10S2 1145.05
11

Route of Synthesis

12

References

13

More Information

Seletalisib

Tags: buy 1362850-20-1 IC50 | 1362850-20-1 price | 1362850-20-1 cost | 1362850-20-1 solubility | 1362850-20-1 purchase | 1362850-20-1 manufacturer | 1362850-20-1 research buy | 1362850-20-1 order | 1362850-20-1 MSDS | 1362850-20-1 chemical structure | 1362850-20-1 Storage condition | 1362850-20-1 molecular weight | 1362850-20-1 mw | 1362850-20-1 datasheet | 1362850-20-1 supplier | 1362850-20-1 cell line | 1362850-20-1 NMR | 1362850-20-1 MS | 1362850-20-1 IR | 1362850-20-1 solubility | 1362850-20-1 Safe information | 1362850-20-1 Qc and Spectral Information | 1362850-20-1 Clinical Information | 1362850-20-1 Clinical Trial | 1362850-20-1 Route of Synthesis | 1362850-20-1 storage condition | 1362850-20-1 diseases and conditions | 1362850-20-1 flash point | 1362850-20-1 boiling point | 1362850-20-1 melting point | 1362850-20-1 storage condition | 1362850-20-1 brand